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Abstract
Background: Loss of UBE3A causes Angelman syndrome, whereas excess UBE3A activity appears to increase the
risk for autism. Despite this powerful association with neurodevelopmental disorders, there is still much to be
learned about UBE3A, including its cellular and subcellular organization in the human brain. The issue is important,
since UBE3A’s localization is integral to its function.
Methods: We used light and electron microscopic immunohistochemistry to study the cellular and subcellular
distribution of UBE3A in the adult human cerebral cortex. Experiments were performed on multiple tissue sources,
but our results focused on optimally preserved material, using surgically resected human temporal cortex of high
ultrastructural quality from nine individuals.
Results: We demonstrate that UBE3A is expressed in both glutamatergic and GABAergic neurons, and to a lesser
extent in glial cells. We find that UBE3A in neurons has a non-uniform subcellular distribution. In somata, UBE3A
preferentially concentrates in euchromatin-rich domains within the nucleus. Electron microscopy reveals that
labeling concentrates in the head and neck of dendritic spines and is excluded from the PSD. Strongest labeling
within the neuropil was found in axon terminals.
Conclusions: By highlighting the subcellular compartments in which UBE3A is likely to function in the human
neocortex, our data provide insight into the diverse functional capacities of this E3 ligase. These anatomical data
may help to elucidate the role of UBE3A in Angelman syndrome and autism spectrum disorder.
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Background
Protein degradation through the ubiquitin-proteasome
pathway (UPP) is important for a wide range of functions
in the nervous system [1, 2]. In UPP processing, the pro-
tein substrate is marked by covalent attachment of the
small protein ubiquitin for subsequent degradation by the
proteasome, a specialized proteolytic complex. The
process starts with the activation of ubiquitin by E1 ubi-
quitin ligase enzymes [3, 4]. E2 enzymes then transfer the
activated ubiquitin to E3 ubiquitin ligases, which attach
the ubiquitin to the substrate. The E3 ligases determine
the substrate specificity of ubiquitination.
Two major classes of E3s have been defined: HECT
(homologous to E6-AP carboxyl-terminus) domain E3s
and RING finger E3s. UBE3A, the first E3 discovered in
the HECT class [5], is of special interest, because failure
to maintain appropriate levels of UBE3A in the brain is
directly linked to severe clinical disorders. The loss of
UBE3A function causes Angelman syndrome (AS) [6, 7],
characterized by profound intellectual and developmen-
tal disabilities [8]. On the other hand, increased UBE3A
activity (via gene duplication or gain-of-function muta-
tion) is implicated in several forms of autism [9–15], im-
plying that UBE3A must be expressed at precise levels
to allow proper neuronal function.
Despite its clinical importance, our current under-
standing of UBE3A’s function in the brain remains lim-
ited. UBE3A has been implicated in regulation of Golgi
acidification [16] and mitochondrial function [17–19], as
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well as synaptic transmission and plasticity [20–26]. Sev-
eral potential interactors and substrates for its ubiquitin
ligase activity have been identified, including the RhoA
guanine nucleotide exchange factors Pbl/ECT2 and
Ephexin5 [24, 27, 28], RAD23A, (an enzyme involved in
excision repair of damaged DNA [29]), and the estrogen
receptor [30]. UBE3A has also been shown to regulate
the levels of Cbln1 in excitatory neurons, which in turn
can influence sociability [26]. Finally, UBE3A can inter-
act directly with the proteasome to influence its de-
gradative activity [15, 31–35], suggesting potentially
wide-ranging roles for UBE3A in cellular functions
that remain to be fully defined.
Crucial for the elucidation of UBE3A’s functions is to
determine where the protein actually lies within the cell.
Previous immunohistochemical studies in rodents found
a broad distribution of UBE3A, but emphasized its nu-
clear expression in mature neurons, consistent with a
proposed role for UBE3A in the regulation of transcrip-
tion [26, 36–38]. However, patterns of UBE3A expres-
sion in humans may not be fully conserved, considering
the 100 million years of divergent evolution between ro-
dents and primates. Unique patterns of UBE3A expres-
sion within the cerebral cortex could have important
functional implications, especially given the cognitive
manifestations of both AS and autism. Here, we explore
this intriguing possibility by investigating the subcellular
distribution of UBE3A in the human temporal cortex.
Methods
Human brain tissue
All procedures regarding human tissue were performed
with the approval of the UCSF Committee on Human Re-
search and the University of Maryland Institutional Re-
view Board. Nine small blocks from postmortem temporal
cortex were obtained from the UCSF Neurodegenerative
Disease Brain Bank (NDBB) and the NIH NeuroBioBank,
including autopsy materials from all three adults with AS
currently available for study. Details are listed in Table 1.
Interpretability of immunohistochemical results depends
on the quality of the tissue. To assess structural preserva-
tion, we used transmission electron microscopy of fixed
samples embedded in epoxy plastic.
The ultrastructural integrity of all postmortem tissue was
seriously compromised. In the best preserved samples,
most subcellular structures were identifiable, but the tissue
contained abnormal holes, neurons were vesiculated, cyto-
plasm was disrupted, nucleoplasm appeared abnormally
condensed, membranes were distorted, and mitochondria
were swollen (Fig. 1a, b). The overall impression was of
substantial deterioration of the material surrounding a
“skeleton” of residual organization. Notwithstanding the
suboptimal integrity of this material, it was far superior to
that of the available postmortem samples from persons
with AS (Fig. 1c, d). This material was markedly degraded,
with severe disruption and a global lack of ultrastructural
integrity. A few elements remained identifiable, including
many synapses, but these resembled biochemically isolated
preparations; synaptic membranes and synaptic vesicles
were typically lost or distorted. We concluded that despite
their inherent clinical importance, the available AS samples
were unsuitable for micro-anatomical study, while autopsy
material from neurotypical controls was acceptable for spe-
cific purposes if results were interpreted with caution. Un-
expectedly, the structural preservation and RIN score
(RNA integrity number) were not always correlated
(Table 1), further emphasizing the value of ultrastructural
assessment.
Choosing to focus on well preserved material, we ob-
tained 9 surgical biopsies. Because of limited tissue avail-
ability, all nine were from patients undergoing surgery
to remove epileptic foci in the hippocampus (Table 2).
The temporal cortex from these patients was intact, dis-
playing normal activity in intraoperative electrocorticogra-
phy, and removed only to gain access to the pathological
hippocampal tissue beneath it. Small pieces of the neocor-
tex overlying the epileptic focus were immersion-fixed for
24 h at 4 °C in 1–4% paraformaldehyde (PFA)/1% glutaral-
dehyde in phosphate buffer (PB), 2% PFA/2–4% glutaral-
dehyde in 0.1 M sodium cacodylate + 0.1% CaCl2 and
Table 1 Autopsy cases included in this study
Repository Case ID Sex Age (years) Clinical diagnosis Time to fixation (hours) RIN
UCSF NDBB P2321.10 M 77 MCI 4.9 3–3.6
UCSF NDBB P2394.12 M 76 Control 8.2 5.2–6.1
UCSF NDBB P2698 M 81 MCI 10 –
Maryland 5363 F 28 Control 11 –
Maryland 5659 M 17 Control 10 6.8
Maryland 5758 F 43 Control 18–23 –
Maryland 1494 F 43 AS 21 –
Maryland 5743 M 19 AS 18–23 –
Maryland 3854 F 21 AS 21 –
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2.5% DMSO, or 4% PFA in 0.1 M sodium cacodylate +
0.1% CaCl2 and 2.5% DMSO. Following fixation, the sam-
ples were stored in PO4-buffered saline (PBS) at 4 °C. Sec-
tions were cut at 50 μm on a Vibratome and collected in
cold PB.
In contrast to the postmortem tissue, the ultrastruc-
tural integrity of the biopsy samples was generally good,
and in many cases, comparable to that obtained from
perfusion-fixed mice (Fig. 1e, f ). Since the biopsies were
from patients undergoing surgery to remove epileptic
Fig. 1 Ultrastructural integrity of human tissue samples from different sources. Ultrastructural integrity is low in postmortem material from a
control donor, though major organelles such as nuclei (N) remain identifiable (low-magnification view, a). At high magnification, synapses
(arrowhead) are damaged but clearly defined (b). Material from an Angelman syndrome donor is virtually uninterpretable (reflecting the practical
difficulty of obtaining and curating such material), though damaged mitochondria and traces of nuclear structure remain (N in panel c); hints of
synaptic specializations may be identified even in this material (arrowhead, d). In contrast, tissue from biopsy specimens obtained during
surgeries for epilepsy shows very good preservation, as documented by features including intact mitochondria, well-aligned rough endoplasmic
reticulum, and intact chromatin (e). The well-preserved neuropil (f) contrasts with that of the autopsy specimens above. Tissue from case no. 5758
for a and b, 1494 for c and d, and Q1012 for e and f. Scale bar = 1 μm in a, c, and e and 500 nm in b, d, and f
Table 2 Biopsy cases included in this study
Case no. Sex Age (years) Clinical diagnosis Time to fixation (minutes)
Q1010 M 30 Epilepsy 15
Q1011 M 44 Epilepsy 6
Q1012 M 58 Epilepsy 10
Q1013 F 38 Epilepsy 6
Q1014 F 48 Epilepsy 10
Q1015 F 66 Epilepsy 7
Q1017 M 46 Epilepsy 7
Q1018 F 20 Epilepsy 5
Q1019 F 51 Epilepsy 4
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foci, we took the added precaution of staining each sam-
ple for parvalbumin, GABA, and glial fibrillary acidic
protein (GFAP), three markers which may undergo
pathological changes in epileptic tissues; we restricted
our analysis to regions from each biopsy that appeared
normal, as assessed by comparison with immunostaining
in perfusion-fixed rodents.
Animals
All procedures related to the care and treatment of ani-
mals were in accordance with institutional and NIH
guidelines, and all animal use protocols were reviewed
and approved by the UNC Institutional Animal Care and
Use Committee. AS model mice (Ube3am−/p+), which ma-
ternally inherit the Ube3a knock-out allele, were gener-
ated by mating wild-type (Ube3am+/p+) male mice to
female mice with paternal inheritance of the Ube3a
knock-out allele (Ube3am+/p–), which themselves are
phenotypically normal [39, 40]. After inducing deep
anesthesia with sodium pentobarbital (80 mg/kg, i.p.),
adult (P60–P100) male mice were intracardially perfused
with 50 ml of 4% freshly depolymerized paraformaldehyde
in phosphate buffer (PB, 0.1 M, pH 7.4), then post-fixed
overnight at 4 °C in the same buffer. To mimic the biopsy
procedure in human patients, we anesthetized mice with
pentobarbital (80 mg/kg) and quickly removed the brain.
One hemisphere was immediately submerged in fixative,
while the other half was exposed to room air for 15 min
prior to immersion in fixative. After 24 h in the fixative,
the brains were rinsed in PB, sectioned at 50 or 100 μm
on aVibratome, and collected in cold PB.
Antibodies
To identify UBE3A, we used a mouse monoclonal anti-
body (3E5, Sigma-Aldrich, cat. no. SAB1404508, RRI-
D:AB_10740376) raised against a peptide corresponding
to mouse UBE3A isoforms 1 and 3 (a.a. 315–415) and
isoform 2 (a.a. 336–436). Importantly, this immunogen
shares 100% sequence identity with human UBE3A iso-
forms 1 (a.a. 318–417), 2 (a.a. 341–441), and 3 (a.a. 338–
437). We used this antibody because we had previously
verified its specificity against AS model and UBE3A KO
mice [41].
To identify GABA, we used a rabbit polyclonal anti-
body (Sigma, St. Louis, MO; A2052, lot 052K4827) de-
veloped using GABA-BSA as the immunogen. The
antibody was affinity-purified using the immunogen. It
showed positive binding with GABA and GABA-KLH in
a dot blot assay and negative binding with bovine serum
albumin (BSA) (manufacturer’s technical information).
To identify GFAP, we used a rabbit polyclonal
anti-GFAP (Chemicon, AB5804) developed against puri-
fied bovine GFAP. This antibody recognizes a 51 kDa
band on immunoblot of rat spinal cord.
To identify Oligodendrocyte Transcription Factor 2
(Olig2), we used a rabbit polyclonal anti-Olig2 (Milli-
pore, AB9610) developed using a recombinant mouse
Olig-2. This antibody specifically labels cells of oligo-
dendrocyte lineage [42], consistent with our own obser-
vations [43].
Light microscopy
Free-floating sections were treated for 30 min in 1% so-
dium borohydride, followed by 30 min with 3% H2O2 in
phosphate-buffered saline (PBS, 0.1 M, pH 7.4). After
preincubation in 10% normal donkey serum (to block
secondary antibody binding sites), sections were incu-
bated in UBE3A (1:500 to 1:5000) overnight on a shaker
at room temperature.
For immunoperoxidase microscopy, sections were then
incubated overnight on a shaker at room temperature in
biotinylated secondary antibody (1:200; Jackson Immu-
noResearch, West Grove, PA) and for 4 h in ExtrAvidin-
peroxidase complex (1:5000; Sigma, St. Louis, MO); per-
oxidase was histochemically visualized with diaminobenzi-
dine. Processed sections were mounted on gelatin-coated
slides, air dried, and cleared with xylene before being cov-
erslipped with D.P.X. Mountant (BDH Chemicals, Poole,
England).
For immunofluorescence, antigenic sites were visual-
ized with donkey IgG conjugated to DyLight 549 (1:200,
Jackson ImmunoResearch; West Grove, PA). For double
labeling, the second primary antibody (1:10,000 GABA,
1:1000 Olig2, or 1:2000 GFAP) was applied overnight
and visualized by a secondary antibody conjugated to
Alexa 488 (1:200, Invitrogen). Some sections were then
counterstained with DAPI (1:10,000, Sigma-Aldrich, cat.
no. D9542) to visualize nuclei, and with NeuroTrace
640–660 (1:1000, Invitrogen, Thermo Fisher Scientific,
Rockford, IL; cat. no. N21483) to visualize neuronal
somata. Sections were examined with a Zeiss LSM 880
confocal microscope with Airyscan.
Electron microscopy
To assess structural preservation, sections were proc-
essed for reduced osmium according to the Knott proto-
col [44, 45]. Briefly, sections were washed in cacodylate
buffer (0.1 M, pH 7.4) and post-fixed for 40 min in 1.5%
potassium ferrocyanide and 1% osmium tetroxide,
followed by 1 h in 1% osmium tetroxide alone, rinsed in
water, then incubated 40 min in 1% uranyl acetate in
water, rinsed in water, dehydrated in an ethanol series,
and infiltrated and embedded in resin (Spurr’s low vis-
cosity epoxy with ERL-4221, Electron Microscopy Sci-
ences, Hatfield, PA; cat. no. 14300).
For immunohistochemistry, sections were treated with
1% sodium borohydride/PBS, followed by 3% H2O2/PBS,
then 0.025% Triton X-100/PBS, then blocked with 10%
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normal goat serum (NGS), and incubated overnight in
primary antibody (UBE3A, 1:200 to 1:1000). Sections
were rinsed, and blocked again in 2% NGS, then incu-
bated overnight with biotinylated goat-anti mouse IgG
(1:2000, Vector Laboratories, Burlingame, CA; cat. no.
BA-9200), rinsed, and incubated for 2 h in 1.4 nm gold
particles conjugated to streptavidin (1:100; Nanoprobes,
Yaphank, NY; cat. no. 2016). After rinsing, binding was
stabilized by treating 30 min in 2% glutaraldehyde/PBS;
sections were washed again and transitioned into 0.05 M
sodium acetate (to remove phosphate and chloride ions),
followed by silver enhancement with HQ Silver (Nanop-
robes, Yaphank, NY; cat. no. 2012). After rinsing in so-
dium acetate and transitioning to PB, sections were
post-fixed in 0.5% osmium tetroxide in 0.1 M PB for
45 min, rinsed and transitioned to 0.1 M maleate buffer,
pH 6, and then incubated for 45 min with 1% uranyl
acetate in maleate buffer (0.1 M, pH 6.0).
After processing, sections were dehydrated in a graded
ethanol series and infiltrated with a low viscosity epoxy resin
(Spurr’s with ERL-4221, Electron Microscopy Sciences, Hat-
field, PA) and flat-mounted between sheets of ACLAR®
fluoropolymer (Electron Microscopy Sciences, Hatfield, PA;
cat. no. 50425) within glass slides. Sixty-nanometer sections
were cut and mounted on 200 mesh copper grids. For
double labeling with GABA, nickel grids were pretreated
15 min at 60 °C in 0.01 M citrate buffer, pH 6, rinsed in
water, blocked in 1% BSA in Tris-buffered saline, pH 7.6,
with 0.005% Tergitol NP-10, and incubated overnight at 21–
24 °C room temperature with the primary antibody (GABA,
1:10,000 to 1:50,000). Grids were rinsed, blocked in 1% nor-
mal goat serum in TBS, pH 8.2, withTergitol NP-10, and in-
cubated in secondary antibodies for 2 h (goat antibody to
rabbit IgG conjugated to 20 nm gold particles, BBI, UK, cat.
no. EM.GAR20). Grids were then rinsed in buffer, then
water, and counterstained with 1% uranyl acetate in water,
followed by Sato’s lead. Electron microscopy was performed
with a Philips Tecnai transmission electron microscope.
Controls
Biopsy specimens are subject to an unavoidable delay
(for our material, 5–15 min, Table 2) prior to immersion
in the fixative. Delayed fixation could in principle lead to
misleading artifacts in immunolocalization, particularly
for a protein involved in proteasomal degradation like
UBE3A. Accordingly, we verified that similarly delayed
immersion fixation in mice does not significantly affect
UBE3A distribution or cause other unforeseen issues.
We compared the overall distribution of UBE3A in
mouse brains fixed by perfusion, immediate immersion
fixation, and immersion fixation after a delay of 15 min
(Fig. 2). We found that UBE3A staining was similar in
all three cases: it was expressed throughout all layers of
the neocortex, with strong nuclear staining and weaker
staining in somata and dendrites. Vascular artifacts and
subtle indications of cytoplasmic condensation after de-
layed fixation did not significantly affect the pattern of
immunostaining.
To verify antibody specificity, we performed the same
procedures on AS model mice (maternal UBE3A
knock-out); only a very weak background staining could
be detected in these mice (Fig. 2e, f ). We conclude that
a 15-min delay in fixation does not significantly alter the
distribution of UBE3A.
Image analysis
To compare the level of nuclear UBE3A between excita-
tory neurons and GABAergic neurons, we acquired 58
random fields of human cortical layers II/III (100 μm×
100 μm, from Q1010, Q1011, and Q1012) from material
quadruple-stained for UBE3A, GABA, NeuroTrace, and
DAPI. To minimize artifacts arising from limited pene-
tration, confocal images were acquired just below the
section surface. For each neuron, the intensity of UBE3A
staining in the nucleus (defined by DAPI) was computed
using FIJI [46]. To control for possible local variations of
immunostaining intensity arising from immersion fixation,
we computed the ratio of staining in GABA-positive and
GABA-negative neurons from each field individually, rea-
soning that NeuroTrace-positive neurons that were immu-
nonegative for GABA were very likely to be excitatory.
To examine the quantitative relationship between
staining for UBE3A and DAPI, we performed intensity
correlation analysis as described by Li et al. [47], using
FIJI. The analysis was performed on 92 random nuclei
from human cortical layers II/III (from Q1010, Q1011,
and Q1012, which yielded particularly robust immuno-
staining for UBE3A). The imaging was done with the
Airyscan mode.
Results
The overall pattern of staining was consistent across bi-
opsy samples from all 9 subjects. UBE3A was found in
neurons throughout the depth of cerebral cortex
(Fig. 3a–c). Staining within neurons concentrated in the
nucleus, but could also be seen in somata and proximal
dendrites, and punctate staining was observed in neuro-
pil (Fig. 3d, e). The apparent lack of nuclear staining in
some neurons was interpreted as an artifact arising from
limited antibody penetration, since it was not seen in
neurons whose nucleus lay at the section edge. Examin-
ation of thin (< 300 nm) sections showed that much of
the nuclear staining was organized into discrete tiny ag-
gregates of DAB reaction product distributed through
the nucleus (Fig. 3f ).
GABAergic deficits have been implicated in the patho-
genesis of neocortical hyperexcitability and epilepsy in
AS model mice [25, 48], and GABA transporter-1 has
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Fig. 2 Immunohistochemistry for UBE3A in mouse cerebral cortex following different methods of fixation. UBE3A staining in tissue fixed by
perfusion (a, b). c, d Immersion fixation of mouse cortex after a delay of 15 min (similar to the fixation for our surgical material) shows only
modest differences, including a subtle condensation of immunopositive cytoplasm. In both cases, UBE3A is expressed through all layers of the
neocortex, with strong nuclear staining and weaker staining in somata and dendrites. UBE3A staining is nearly absent in the brain of an AS model
mouse fixed by immersion after a delay of 15 min (e, f), further confirming specificity of the UBE3A antibody in brain tissue harvested under
conditions similar to surgical biopsy. Scale bar = 100 μm in a, c, and e and 25 μm in b, d, and f
Fig. 3 UBE3A expression in temporal cortex from a human biopsy specimen. a Immunoperoxidase staining for UBE3A. As can be seen by
comparison with adjacent Nissl-stained section (b), the large majority of neurons are immunopositive. c Enlargement of boxed area from a;
UBE3A is expressed throughout all layers of temporal cortex. d, e Higher magnification micrographs show UBE3A concentrating in nuclei. Antigen
is also visible in somata and neuropil, but at lower levels. f High magnification micrograph of a 250-nm plastic section shows discrete grains of
immunoperoxidase reaction product scattered through most of the nucleus, but seemingly excluded from certain regions. Tissue from case no.
Q1019. Scale bar = 1 mm in a and b, 250 μm in c, 50 μm in d, 25 μm in e, and 10 μm in f
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been proposed as a potential UBE3A substrate [49]. To
determine whether UBE3A is expressed in inhibitory
neurons of the human neocortex, as it is in mice, we
performed double labeling with GABA (Fig. 4). We
found that GABAergic neurons, like pyramidal neurons,
express higher levels of UBE3A in their nuclei than in
their somata. However, quantitative analysis of biopsy ma-
terial from three subjects revealed that the concentration
of nuclear UBE3A is ~ 40% (38 ± 6.4%, n = 51) higher in
pyramidal neurons than in GABAegic neurons. In
addition, colocalization was observed in fine processes
and puncta distributed through the neuropil (Fig. 4c, d).
In mice, UBE3A is expressed not only in neurons but also
neuroglia. To evaluate its distribution in non-neuronal cells
in the human temporal cortex, we performed double stain-
ing with Olig2, to identify oligodendrocytes (Fig. 5a, b).
Indeed Olig2-positive somata were consistently immunopo-
sitive for UBE3A, though to a lesser degree than seen in
neurons. We also performed double staining with GFAP to
identify astrocytes, finding that astrocytes also expressed
UBE3A, though generally at lower levels than either neu-
rons or oligodendrocytes (Fig. 5c, d). These patterns were
reminiscent of UBE3A staining of neuroglia in the mouse
brain [43].
To get a better understanding of the subcellular
organization of UBE3A, we performed high-resolution im-
munofluorescence microscopy. In images prepared using
an Airyscan confocal microscope (Fig. 6), UBE3A staining
appeared as discrete puncta whose density was high in the
nucleus and also present (though at lower densities) in
somata and proximal dendrites; scattered puncta of
immunolabel were seen in neuropil (Fig. 6a). In the nu-
cleus, UBE3A puncta were interspersed with DAPI “hot-
spots,” but did not overlap with them (Fig. 6b, c).
Likewise, UBE3A staining seemed to be excluded from
nucleoli (Nu, Fig. 6b). To more directly test the rela-
tionship between UBE3A and DNA condensation, we
computed the intensity correlation quotient [47] (ICQ,
computed such that − 0.5 represents perfect negative co-
variance and 0.5 represents perfect positive covariance be-
tween two antigens) for 92 nuclei from 3 humans Q1010,
Q1011, and Q1012 (Fig. 7). We found an average ICQ of
− 0.04 ± 0.005, showing that UBE3A and DAPI staining
negatively co-vary, confirming our qualitative impression
that UBE3A is excluded from regions of condensed DNA.
We used electron microscopy to examine the subcellu-
lar organization of UBE3A with higher precision, using
pre-embedding immunogold labeling followed by silver
Fig. 4 UBE3A expression in GABAergic neurons in temporal cortex from a human biopsy specimen. a Double labeling reveals UBE3A in the
nuclei and somata of GABAergic neurons (arrows). b A pyramidal neuron immunopositive for UBE3A is surrounded by numerous GABA-positive
structures likely to represent cross sections of dendrites and axon terminals. Enlargements in c and d show the presence of UBE3A in some of
these small GABA-positive structures. Tissue from case no. Q1010. Scale bar = 50 μm in a, 10 μm in b, and 2 μm in c and d
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intensification (Fig. 8). We focused our attention on
layers II–III as we had done previously for mouse [41].
Labeling was prominent in nuclei but was also present
in somatic cytoplasm and neuropil, echoing the results
from light microscopy (Fig. 6). In the nucleus, UBE3A
labeling was largely restricted to euchromatin domains;
very little labeling was found over electron-dense hetero-
chromatin zones (Fig. 8a, b), as was predicted by our ICQ
analysis of UBE3A/DAPI colocalization (Fig. 7). UBE3A
was also excluded from nuclear organelles such as nucle-
oli. Occasional gold/silver particles were associated with
the nuclear membrane. In neuronal cytoplasm, UBE3A
was seen decorating the Golgi apparatus and was
associated with the outer mitochondrial membrane
(Fig. 8c, d). In dendrites, labeling was often associated
with the plasma membrane and with poorly defined
tubulo-vesicular endomembranous structures. In den-
dritic spines, labeling was within the spine head and
neck, including the spine apparatus, but was not found
at the PSD (Fig. 8e). The majority of labeling within the
neuropil was found in axon terminals making axospi-
nous, axodendritic, and axosomatic synapses (Fig. 8e, f ).
In axon terminals, UBE3A associated with the plasma
membrane and over clusters of presynaptic vesicles, but
did not show a special affinity for the active zone.
Double labeling experiments showed that UBE3A is
expressed in GABAergic terminals (Fig. 8g).
Discussion
While previous studies have examined human UBE3A
expression using Western blot analysis [50, 51] and in
human-induced pluripotent stem cells [52, 53], the
present work provides the first high-resolution descrip-
tion of the subcellular distribution of UBE3A in the hu-
man brain. Though reporting only the presence of a
molecule, not its functional level of activity, immunohis-
tochemistry can shed light on important aspects of hu-
man neurophysiology and neuropathology inaccessible
Fig. 5 UBE3A expression in neuroglia in temporal cortex from human biopsy specimen. a, b Double labeling reveals UBE3A in the nuclei and
somata of Olig2-positive glia (oligodendrocytes, arrowheads). However, UBE3A staining in Olig2-positive glia (b, arrowhead) is appears weaker
than in neurons (b, arrow). c Double labeling reveals UBE3A in the nuclei and somata in GFAP-positive cells (astrocytes). UBE3A in GFAP-positive
cells is at lower levels than in neurons and Olig2-positive glia. Tissue from case no. Q1010. Scale bar = 50 μm in a, 10 μm in b and c, and 5 μm in d
Burette et al. Molecular Autism            (2018) 9:54 Page 8 of 14
by even the most sensitive contemporary methods of live
brain imaging. However, immunohistochemistry may be
misleading unless tissue of excellent quality is studied.
The potential for error is particularly troublesome when
tissue of poor quality is examined using super-resolution
methods. Several indirect methods are customarily used
to assess the quality of human histological material in-
cluding tissue pH and specific markers of RNA quality
[54]. We used electron microscopy to assess tissue quality
directly, finding that histological and immunocytochem-
ical staining at the light microscopic level can appear to be
satisfactory even in material that has been severely de-
graded, potentially resulting in misleading results.
Based on examination of surgically resected tissue of
high ultrastructural quality, we conclude that UBE3A is
broadly expressed by both excitatory (pyramidal) and
inhibitory (GABAergic) neurons of the human cerebral
cortex. Epilepsy, a common comorbidity in AS, is thought
to reflect a disrupted balance between excitatory and in-
hibitory neurotransmission. We recently demonstrated in
an animal model that selective deletion of Ube3a in
GABAergic neurons causes both circuit hyperexcitability
and seizures; the presence of UBE3A in inhibitory neurons
of the human neocortex further supports the hypothesis
that GABAergic neurons play a key role in precipitating
the electroencephalographic abnormalities and epilepsy
seen in AS.
UBE3A may also serve important functions in glia.
For example, flies with glia-specific overexpression of
Dube3a (the fly UBE3A homolog) display a robust seiz-
ure phenotype, suggesting a possible role for glial
UBE3A in Dup15q pathophysiology [55]. Our finding
Fig. 6 High magnification immunofluorescence, showing UBE3A (green) in two pyramidal neurons in layer V in temporal cortex from human
biopsy specimen (a). Sections were counterstained with DAPI (red) to visualize nuclei. UBE3A staining is organized into small puncta that
concentrate in neuronal nuclei. Small UBE3A-positive puncta are visible in somata and proximal dendrites, and throughout the neuropil.
Successive enlargements (b, c) show that UBE3A puncta are excluded from the nucleolus (Nu) and from DAPI “hotspots.” Scale bar = 10 μm in a,
5 μm in b, and 1 μm in c. Tissue from case no. Q1019
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that UBE3A is also expressed in glia in the human brain
(though at a lower level than in neurons) is consistent
with this possibility.
We found that UBE3A is expressed in multiple subcel-
lular compartments. In neurons, it concentrates in
euchromatin-rich domains within the nucleus, where it
is positioned to regulate the expression of active genes,
possibly exerting cell-wide global effects. A recent study
shows that increasing UBE3A in the nucleus downregu-
lates the glutamatergic synapse organizer Cbln1 [26],
leading to weakened glutamatergic transmission; the
same study found impaired sociability in these mutant
mice, providing a possible explanation for how UBE3A
overexpression might lead to autism spectrum disorder.
Nuclear UBE3A may also perform additional roles. Like
other ubiquitin E3 ligases, UBE3A may modulate the
abundance and activity of transcriptional activators via
its ubiquitin-protein ligase activity, thus modulating the
formation of transcriptional complexes at genes and
regulating chromatin structure [56]. UBE3A might also
act more directly within the nucleus as a transcriptional
co-regulator [36, 57–59].
UBE3A labeling was also associated with mitochondria.
Loss of UBE3A has been linked to key enzymatic deficits
in the mitochondrial respiratory chain [17, 18]. A role for
mitochondrial abnormalities in the pathogenesis of autism
spectrum disorders has also been suggested [60], and
mitochondrial dysfunction has been shown in autistic pa-
tients with 15q inverted duplication [61].
The enrichment of UBE3A that we observed in both
excitatory and GABAergic axon terminals and (to a
lesser extent) in dendritic spines is of special interest
since both Dup15q and AS mouse models show synaptic
deficits [13, 25, 62]. Postsynaptically, abnormal function
of excitatory synapses in UBE3A mutant mice has been
linked to decreased UBE3A-mediated proteasomal
degradation of the RhoA guanine exchange factor
Ephexin5 and to pathways modulated by the synaptic
protein Arc [23, 24, 58, 63]. UBE3A has also been shown
to target the small-conductance potassium channel SK2 for
Fig. 7 Quantification of the reciprocal localization of UBE3A and DAPI in human neuronal nuclei. To analyze the relationship between UBE3A and
DAPI in neuronal nuclei, we used the intensity correlation analysis approach of Li et al. [47]. Analyses are presented as intensity correlation plots:
the x value, (channel 1 pixel value–channel 1 mean value) × (channel 2 value–channel 2 mean value), reflect the covariance of both channels, and
the y value reflects the intensity of channels 1 or 2. Pixels with values situated left of the x = 0 line do not colocalize or have inversely correlated
intensities, whereas pixels situated on the right side colocalize (see diagram in a). Scatterplot in b and c corresponds to the nuclear region of the
sections used for illustration in Fig. 6b (Scatterplots are from raw confocal images, while contrast and brightness were adjusted in the micrographs).
Panel c shows DAPI with respect to UBE3A, and d shows UBE3A with respect to DAPI. Both plots are skewed toward negative values, implying that
UBE3A and DAPI pixel intensity co-varies in opposite directions. d Box and whiskers plot of intensity correlation quotient (ICQ, [47]) from 92 nuclei
from layers II–III. ICQ values ~ 0 imply random staining, 0 > ICQ≥− 0.5 indicate segregated (negatively correlated) staining, and 0 < ICQ≤ + 0.5 indicate
dependent (positively correlated) staining. We found an average ICQ of − 0.04 ± 0.005, showing that UBE3A and DAPI staining negatively co-vary
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degradation. Decreased NMDA receptor activation due to
an elevated SK2 protein level may underlie the impaired
LTP seen in AS model mice [62]. Presynaptically, the
localization of UBE3A over vesicle clusters is surprising,
since no integral synaptic vesicle proteins have yet been
identified as targets for UBE3A [64]. However, UBE3A does
appear to modulate the degradation of α-synuclein, a protein
closely associated with synaptic vesicles [65–68], and loss of
UBE3A can alter rates of synaptic depression [25, 48]. Al-
though the mechanistic basis of UBE3A-associated synaptic
disruption remains unclear, our data support a role for
UBE3A in regulating synapses in the human neocortex.
The overall pattern of UBE3A immunoreactivity we
found in human temporal cortex is generally consistent
with that seen in previous studies of rodent cortex, re-
inforcing the idea that mice offer a valuable model in
which to study the role of UBE3A in the brain. Mouse
models of AS display many Angelman-like phenotypes,
including learning and memory deficits, motor dysfunction,
and seizures, while transgenic mice expressing UBE3A
Fig. 8 Pre-embedding immunogold labeling for UBE3A in layer II/III lateral temporal cortex from human biopsy specimen. a, b UBE3A labeling in
nucleus (colorized in blue); labeling is over euchromatin (Ec) domains, but is not associated with heterochromatin (Hc) or nucleoli (Nu). c UBE3A
labeling associated with endomembranes of the Golgi apparatus. d UBE3A labeling in cytoplasm; arrows point to label associated with
mitochondria. e, f UBE3A labeling in presynaptic terminals (colorized in green) and a dendritic spine (colorized in red). g A GABAegic terminal
(colorized in yellow) labeled for UBE3A (pre-embedding, irregular 30–50 nm particles of silver-intensified immunogold, arrowheads) and GABA
(post-embedding, 20 nm gold). Tissue from case no. Q1010 in a, c, d, e, and f and Q1019 in b and g. Scale bar = 1 μm in a and b, 250 nm in c
and g, and 500 nm in d–f
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at increased dosages manifest several core autistic be-
havioral traits [26]. Nevertheless, some divergence be-
tween mouse and human UBE3A expression is likely.
In particular, regulatory elements may have evolved in
humans to sculpt UBE3A expression (which is spatio-
temporally ubiquitous in the mouse) into unique and
discrete patterns across the neocortex and throughout
the cerebrum during development [69]. This remains
to be tested in diverse samples of the developing and
adult human brain.
Conclusions
That UBE3A is expressed at high levels in both excitatory
and inhibitory neurons in the human cerebral cortex points
to the many ways that its dysregulation might disrupt cir-
cuit function, while its concentration at synapses and in nu-
clei offers intriguing functional clues. UBE3A in axon
terminals presumably regulates the function of individual
synapses; in contrast, its concentration in euchromatin-rich
nuclear domains suggests that UBE3A may also mediate
global effects on neuronal physiology, by regulating gene
transcription. This information identifies axon terminals
and nuclei as two distinct potential targets for future clin-
ical intervention.
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